Anke Verlinden

Anke Verlinden


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2020 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
O(on behalf of the Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT)
on behalf of the Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT)
AVAnke Verlinden
Anke Verlinden
MMMalgorzata Mikulska
Malgorzata Mikulska
NKNina Simone Knelange
Nina Simone Knelange
DADina Averbuch
Dina Averbuch
JSJan Styczynski
Jan Styczynski
The aim of this survey was to summarize the current antimicrobial practice in febrile neutropenia and the presence of key aspects of antimicrobial stewardship. A questionnaire was sent to 567 centers, and complete responses were obtained from 194 (34.2%). Fluoroquinolone and co-trimoxazole prophylaxis are used in 57.1% and 89.1%, respectively. In 66.4%, the first-line empirical therapy is piperacillin/tazobactam, whereas 10.9% use carbapenems. Empirical combination therapy is used in stable patients without history of resistant pathogens in 37.4%. De-escalation to monotherapy is performed within 3 days in 35.3% and after 10 days in 19.1%. Empirical addition of a glycopeptide is performed when fever persists more than 2–3 days in 60.8%. Empirical escalation to a broader spectrum agent is performed when fever persists more than 3–5 days in 71.4%. In case of positive blood cultures with a susceptible pathogen and uncomplicated presentation, 76.7% of centers de-escalate and 36.6% discontinue before neutrophil recovery. In fever of unknown origin with uncomplicated presentation, 54.1% of centers de-escalate and 49.5% discontinue before neutrophil recovery. Recommendations put forward in the ECIL guidelines are not widely implemented in clinical practice. Specific problems include overuse of carbapenems and combination therapy and unjustified addition of glycopeptides without further de-escalation or discontinuation.

23 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
AVAnke Verlinden
Anke Verlinden
HJHilde Jansens
Hilde Jansens
HGHerman Goossens
Herman Goossens
SASébastien Anguille
Sébastien Anguille
ZBZwi N Berneman
Zwi N Berneman
AGAlain P Gadisseur
Alain P Gadisseur
There is currently no consensus on optimal duration of antibiotic treatment in febrile neutropenia. We report on the clinical impact of implementation of antibiotic de-escalation and discontinuation strategies based on the Fourth European Conference on Infections in Leukaemia (ECIL-4) recommendations in high-risk hematological patients. We studied 446 admissions after introduction of an ECIL-4–based protocol (hereafter “ECIL-4 group”) in comparison to a historic cohort of 512 admissions. Primary clinical endpoints were the incidence of infectious complications including septic shock, infection-related intensive care unit (ICU) admission, and overall mortality. Secondary endpoints included the incidence of recurrent fever, bacteremia, and antibiotic consumption. Bacteremia occurred more frequently in the ECIL-4 group (46.9% [209/446] vs 30.5% [156/512]; P < .001), without an associated increase in septic shock (4.7% [21/446] vs 4.5% [23/512]; P = .878) or infection-related ICU admission (4.9% [22/446] vs 4.1% [21/512]; P = .424). Overall mortality was significantly lower in the ECIL-4 group (0.7% [3/446] vs 2.7% [14/512]; P = .016), resulting mainly from a decrease in infection-related mortality (0.4% [2/446] vs 1.8% [9/512]; P = .058). Antibiotic consumption was significantly reduced by a median of 2 days on antibiotic therapy (12 vs 14; P = .001) and 7 daily antibiotic doses (17 vs 24; P < .001) per admission period. Our results support implementation of ECIL-4 recommendations to be both safe and effective based on real-world data in a large high-risk patient population. We found no increase in infectious complications and total antibiotic exposure was significantly reduced.

21 April 2014 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AVAnke Verlinden
Anke Verlinden
HJHilde Jansens
Hilde Jansens
HGHerman Goossens
Herman Goossens
AVAnn L. van de Velde
Ann L. van de Velde
WSWilfried A. Schroyens
Wilfried A. Schroyens
AGAlain P. Gadisseur
Alain P. Gadisseur

24 August 2013 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
PDF file
AVAnke Verlinden
Anke Verlinden
AVAnn Van de Velde
Ann Van de Velde
GVGert A. Verpooten
Gert A. Verpooten
KDKarin Janssen van Doorn
Karin Janssen van Doorn

21 May 2021 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AVAnke Verlinden
Anke Verlinden
WSWilfried A. Schroyens
Wilfried A. Schroyens
AGAlain P. Gadisseur
Alain P. Gadisseur

11 April 2017 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
NGNikki Charlotta Paul Granacher
Nikki Charlotta Paul Granacher
ZBZwi N. Berneman
Zwi N. Berneman
WSWilfried Schroyens
Wilfried Schroyens
AVAnn L. R. Van de Velde
Ann L. R. Van de Velde
AVAnke Verlinden
Anke Verlinden
AGAlain P. A. Gadisseur
Alain P. A. Gadisseur
Osteolytic bone lesions and hypercalcemia without peripheral blasts B-cell acute lymphoblastic leukemia (B-ALL) is reported in children but rarely seen in adults. We describe the case of a 34-year old man presenting with hypercalcemia and symptomatic osteolytic bone lesions of vertebrae and ribs who was initially suspected as having a solid malignancy. Diagnostic work-up including peripheral blood examination, radiographic and nuclear studies could, however, not detect a primary tumor. Because of a mild thrombocytopenia and the lack of a primary focus, a bone marrow biopsy was performed leading to the diagnosis of Philadelphia chromosome positive precursor B-ALL. After correction of the hypercalcemia with intravenous fluid administration, corticoids and bisphosphonates, the patient was treated according to the HOVON 100 protocol achieving complete molecular remission after the first cycle of induction chemotherapy. Hypercalcemia and osteolytic bone lesions are rare complications of adult B-ALL and can occur in the absence of peripheral blastosis. With this case report we would like to emphasize the importance of clinical awareness. Immediate treatment of hypercalcemia and initiation of antileukemic treatment is mandatory as a delay of diagnosis might pose a real and possible life-threatening risk in these patients.